Zagouri F, Dimopoulos M A, Bournakis E, Papadimitriou C A
Department of Clinical Therapeutics, Alexandra Hospital, University of Athens School of Medicine, Athens, Greece.
Eur J Gynaecol Oncol. 2010;31(3):268-77.
Epithelial cancer of the ovary is the most lethal malignancy of all gynaecological cancers. Various clinical and pathological features of ovarian cancer are used as predictors of clinical outcome. The use of molecular markers in common clinical practice seems promising for the diagnosis and prognostication. The aim of this review article is to describe current theories regarding the pathogenesis and molecular evolution of epithelial ovarian cancer. With respect to the molecules involved, this article focuses on whether they are associated with poor prognosis or not. This evaluation is performed in light of the progress made and the potential usefulness in treatment decisions without overlooking existing controversies that should be further studied. It is tempting to anticipate the gradual integration of molecular profiling in clinical practice.
卵巢上皮癌是所有妇科癌症中致死率最高的恶性肿瘤。卵巢癌的各种临床和病理特征被用作临床结局的预测指标。在普通临床实践中使用分子标志物进行诊断和预后评估似乎很有前景。这篇综述文章的目的是描述关于上皮性卵巢癌发病机制和分子演变的当前理论。关于所涉及的分子，本文重点关注它们是否与预后不良相关。这一评估是根据已取得的进展以及在治疗决策中的潜在用途进行的，同时不忽视那些有待进一步研究的现有争议。可以预见，分子谱分析将逐渐融入临床实践。
